Abstract: Antigens capable of eliciting antibodies which can enhance the rate of chemical reactions at peptide bonds are disclosed. In particular, the rate of cleavage or formation of metastable peptide bonds, such as ASN-X, ASP-X, GLN-X, GLU-X, LYS-X, and HIS-Y-X, where X and Y are any amino acid, is enhanced by antibodies elicited by said antigen.

Abstract: A labeled substance comprising a biological substance linked to a luminescent rhenium-containing label. Qualitative and quantitative electrochemiluminescent assays using the same. These methods comprise contacting a sample with a reagent labeled with an electrochemiluminescent chemical moiety containing rhenium and capable of combining with the analyte of interest, exposing the resulting sample to chemical, electrochemical, or electromagnetic energy and detecting electromagnetic radiation emitted by the electrochemiluminescent chemical moiety.

Abstract: Qualitative and quantitative electrochemiluminescent assays for analytes of interest present in multicomponent liquids are provided. These methods comprise contacting a sample with a reagent labeled with an electrochemiluminescent chemical moiety and capable of combining with the analyte of interest, exposing the resulting sample to electrochemical energy and detecting electromagnetic radiation emitted by the electrochemiluminescent chemical moiety.

Abstract: This invention pertains to the general field of chemical and biological assays which employ electrochemiluminscence (ECL), also referred to as electrogenerated chemiluminescence. More particularly, the present invention pertains to certain classes of chemical moieties which strongly quench ECL, and the use of these ECL quenchers in combination with ECL labels, for example, in ECL assay methods which employ an ECL quencher and an ECL label. One class of such quenching moieties are those which comprise at least one benzene moiety. Sub-classes of such quenching moieties are those which comprise at least one phenol moiety, quinone moiety, benzene carboxylic acid, and/or benzene carboxylate moiety.

Abstract: Novel chemical analogs of the methadone metabolite 2-ethylidene-1,5-dimethyl-3,3-diphenylpyrrolidine (EDDP) are disclosed. The derivatives can be used for formation of EDDP-protein conjugates. The conjugates can be used in turn to raise antibodies reactive with EDDP and having a low cross-reactivity with methadone. The antibodies and EDDP-enzyme polypeptide conjugates provide the basis for specific immunoassays used in monitoring compliance with methadone treatment.

Abstract: The invention relates to luminescent chimeric proteins which include a photoprotein and a second protein which may be light- or heavy-chain immunoglobulin, an antigenic peptide, avidin, streptavidin, or protein A. The invention also relates to chimeric protein genes, plasmids containing said gene, and hosts transformed with said plasmid. The invention also relates to a range of highly sensitive immunoassays which use the chimeric proteins.

Abstract: A method for increasing the rate of a chemical reaction involving conversion of at least one reactant to at least one product which comprises contacting the reactant with at least one appropriate monoclonal antibody to the reactant under suitable conditions permitting formation of a complex between the monoclonal antibody and the reactant, conversion of the reactant to the product and release of the product from the complex, the monoclonal antibody being characterized by a K>1, where K=k.sub.r /k.sub.p, k.sub.r is the affinity constant of the monoclonal antibody for the reactant and k.sub.p is the affinity constant of the monoclonal antibody for the product, by an r.sub.1 >r.sub.0, where r.sub.1 is the rate of formation of the complex between the antibody and the reactant and where r.sub.0 is the rate of the chemical reaction in the absence of monclonal antibody, by an r.sub.2 >r.sub.0, where r.sub.2 is the rate of the conversion of the complexed reactant to the complexed product and by an r.sub.

Abstract: Specific, selective inhibitors of catalytic antibodies both synthetic and naturally occurring, their use and compositions thereof are disclosed. In particular, an inhibitor preventing the hydrolysis of the peptide bond between amino acid residues 16 and 17 in the neurotransmitter vasoactive intestinal peptide (VIP) by an anti-VIP catalytic autoantibody is disclosed.

Abstract: Formation of an intramolecular cross-link in enzyme donor polypeptide fragments of .beta.-galactosidase, thereby forming a cyclic enzyme donor which is hindered from complementation with an enzyme acceptor fragment to form active of .beta.-galactosidase. The cyclic enzyme donor can be linearized by cleaving to restore complementation ability. Assays in which such cyclic enzyme donors are linearized by specific analytes are disclosed, as well as novel homobifunctional bis-maleimido cross-linking agents of the formula ##STR1## wherein R is hydroxy or acetate.

Abstract: Formation of an intramolecular cross-link in enzyme donor polypeptide fragments of .beta.-galactosidase, thereby forming a cyclic enzyme donor which is hindered from complementation with an enzyme acceptor fragment to form active of .beta.-galactosidase. The cyclic enzyme donor can be linearized by cleaving to restore complementation ability. Assays in which such cyclic enzyme donors are linearized by specific analytes are disclosed, as well as novel homobifunctional bis-maleimido cross-linking agents of the formula ##STR1## wherein R is hydroxy or acetate.

Abstract: Antigens capable of eliciting antibodies which can catalyze chemical reactions, in particular, the cleavage or formation of a peptide linkage, comprising a hapten or a hapten and a suitable carrier molecule are disclosed. Haptens include, among others, silicon and boron containing compounds. Antibodies which are catalytically active for chemical reactions, in particular, the cleavage or formation of a selected peptide linkage or an ester bond, and which are elicited by such antigens are disclosed as well as methods for producing the antibodies and methods for catalyzing the cleavage or formation of a peptide linkage or in ester bond in a molecule.

Abstract: Electrochemiluminiscent moieties having the formula?Re(P).sub.m (L.sup.1).sub.n (L.sup.2).sub.o (L.sup.3).sub.p (L.sup.4).sub.q (L.sup.5).sub.r (L.sup.6).sub.s !.sub.t (B).sub.uwhereinP is a polydentate ligand of Re;L.sup.1, L.sup.2, L.sup.3, L.sup.4, L.sup.5 and L.sup.6 are ligands of Re, each of which may be the same as or different from each other ligand;B is a substance which is a ligand of Re or is conjugated to one or more of P, L.sup.1, L.sup.2, L.sup.3, L.sup.4, L.sup.5 or L.sup.6 ;m is an integer equal to or greater than 1;each of n, o, p, q, r and s is zero or an integer;t is an integer equal to or greater than 1; andu is an integer equal to or greater than 1;P, L.sup.1, L.sup.2, L.sup.3, L.sup.4, L.sup.5, L.sup.6 and B being of such composition and number that the chemical moiety can be induced to emit electromagnetic radiation and the total number of bonds to Re provided by the ligands of Re being equal to the coordination of Reare disclosed.

Abstract: Formation of an intramolecular cross-link in enzyme donor polypeptide fragments of .beta.-galactosidase, thereby forming a cyclic enzyme donor which is hindered from complementation with an enzyme acceptor fragment to form active of .beta.-galactosidase. The cyclic enzyme donor can be linearized by cleaving to restore complementation ability. Assays in which such cyclic enzyme donors are linearized by specific analytes are disclosed, as well as novel homobifunctional bis-maleimido cross-linking agents of the formula ##STR1## wherein R is hydroxy or acetate.

Abstract: Electrochemiluminiscent moieties having the formula?Re(P).sub.m (L.sup.1).sub.n (L.sup.2).sub.o (L.sup.3).sub.p (L.sup.4).sub.q (L.sup.5).sub.r (L.sup.6).sub.s !.sub.t (B).sub.uwhereinP is a polydentate ligand of Re;L.sup.1, L.sup.2, L.sup.3, L.sup.4, L.sup.5 and L.sup.6 are ligands of Re, each of which may be the same as or different from each other ligand;B is a substance which is a ligand of Re or is conjugated to one or more of P, L.sup.1, L.sup.2, L.sup.3, L.sup.4, L.sup.5 or L.sup.6 ;m is an integer equal to or greater than 1;each of n, o, p, q, r and s is zero or an integer;t is an integer equal to or greater than 1; andu is an integer equal to or greater than 1;P, L.sup.1, L.sup.2, L.sup.3, L.sup.4, L.sup.5, L.sup.6 and B being of such composition and number that the chemical moiety can be induced to emit electromagnetic radiation and the total number of bonds to Re provided by the ligands of Re being equal to the coordination of Reare disclosed.

Abstract: Catalytic antibody components, methods for producing catalytic antibody components, methods for using catalytic antibody components, in particular, single chain and smaller components are disclosed. Catalytic antibody components able to promote the cleavage or formation of an amide, peptide, ester or glycosidic bond, and which are prepared from monoclonal catalytic antibodies, catalytic autoantibodies or by site-directed mutagenesis are disclosed. Methods of using catalytic antibody components alone or in combination with other antibody components or other biological moieties are disclosed.

Abstract: The present invention describes cyclopropylindole cytotoxic prodrugs of formulas (I), (II) and (III) as shown in the specification. The present invention is also directed to a method for the site-specific treatment of neoplastic diseases in a mammal which method includes the following steps: (i) administering to an afflicted mammal an effective amount of a targeting agent- enzyme donor peptide conjugate wherein the targeting agent is selected from the group of antibodies, monoclonal antibodies, adhesion molecules and tumor cell surface binding ligands; (ii) administering to the afflicted mammal an effective amount of an enzyme acceptor dimer thereby forming active enzymatic sites at a tumor cell surface; and (iii) administering to the afflicted mammal a therapeutically effective amount of an enzyme-activateable, cytotoxic pro-drug thereby releasing the cytotoxic drug at the tumor site.

Abstract: Electrochemiluminescent moieties having the formula(Re(P).sub.m (L.sup.1).sub.n (L.sup.2).sub.o (L.sup.3).sub.p (L.sup.4).sub.t (B).sub.uwhereinP is a polydentate ligand of Re;L.sup.1, L.sup.2, L.sup.3 and L.sup.4 are ligands of Re, each of which may be the same as or not the same as each other ligand;B is a substance which is a ligand of Re or is conjugated to one or more of P, L.sup.1, L.sup.2, L.sup.3 and L.sup.4 ;m is an integer equal to or greater than 1;each of n, o, p, q, r and s is zero or an integer;t is an integer equal to or greater than 1; andu is an integer equal to or greater than 1;P, L.sup.1, L.sup.2, L.sup.3, L.sup.4 and B being of such composition and number that the chemical moiety can be induced to electrochemiluminesce and the total number of bonds to Re provided by the ligands of Re being equal to the coordination number of Re are disclosed.

Abstract: A tape applicator for application of a double-sided adhesive tape to a member which can be cut and assembled to form a frame for glazing for a skylight, a window or a door. The tape applicator includes a spindle for accepting a plurality of rolls of tape and apparatus for guiding the frame member past the roll of tape to permit accurate and dependable application of the tape to the frame member. A spring mounted block urges the tape into tight, adhesively bonded relation with the frame member at the desired location. The guiding apparatus is removable to allow selection and installation of an appropriate guiding apparatus configured to accept the cross-sectional size and shape of the particular frame member to which it is desired to apply tape. A wall acts as a stop to align the tape with the frame member. When the tape from a particular roll has been exhausted, the remaining core can be pushed past the wall into a recess to allow advancement of the next available roll into position.

Abstract: Catalytic antibody components, methods for producing catalytic antibody components, methods for using catalytic antibody components, in particular, single chain and smaller components are disclosed. Catalytic antibody components able to promote the cleavage or formation of an amide, peptide, ester or glycosidic bond, and which are prepared from monoclonal catalytic antibodies, catalytic autoantibodies or by site-directed mutagenesis are disclosed. Methods of using catalytic antibody components alone or in combination with other antibody components or other biological moieties are disclosed.

Abstract: Specific, selective inhibitors of catalytic antibodies both synthetic and naturally occurring, their use and compositions thereof are disclosed. In particular, an inhibitor preventing the hydrolysis of the peptide bond between amino acid residues 16 and 17 in the neurotransmitter vasoactive intestinal peptide (VIP) by an anti-VIP catalytic autoantibody is disclosed.